Pfizer Patent on Known Substance: A Section 3(d) Analysis
This post examines Pfizer’s patent application on a known substance and the Indian Patent Office’s refusal in light of Section 3d and the Novartis decision. It discusses whether…
Patentability
42 articles
Pfizer falls prey to Section 3(d)
This post analyses the Indian Patent Office’s rejection of Pfizer’s Tofacitinib patent under Section 3(d). The decision addresses issues of novelty, inventive step, and the requirement for evidence…